+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Investigation Report on China's Moxifloxacin Market 2021-2025

  • ID: 5345910
  • Report
  • June 2021
  • Region: China
  • China Research & Intelligence

FEATURED COMPANIES

  • Bayer Vital GmbH
Moxifloxacin is a fourth-generation synthetic quinolone antibacterial drug (8-methoxy-fluoroquinolone antibiotic) developed by Bayer Vital GmbH. It was approved for marketing by the FDA in December 1999. Moxifloxacin can be used to treat several infections, including respiratory infections, cellulitis, anthracnose, endocarditis, intra-abdominal infections, meningitis and tuberculosis. In 2002, Moxifloxacin tablets (400mg) were launched in China. In 2004, Moxifloxacin injection was launched for the treatment of adults suffering from upper and lower respiratory tract infections. In the first half of 2021, in addition to Bayer Vital GmbH, there are several manufacturers in the Moxifloxacin market in China, such as Nanjing Youke Pharmaceutical Co., Ltd., Chengdu Tiantaishan Pharmaceutical Co., Ltd., Chengdu Zhengkang Pharmaceutical Co., Ltd. and Jiangsu Zhengda Fenghai Pharmaceutical Co., Ltd.

The survey data shows that the sales value of Moxifloxacin has grown steadily from 2016 to 2019 in China. In 2020, the sales value of Moxifloxacin fell by 41.23% in China, from CNY1.882 billion in 2019 to CNY1.106 billion in 2020. Due to the second batch of state-organized centralized procurement of medicines, and manufacturers of Moxifloxacin compete by reducing prices. Moxifloxacin of Bayer Vital GmbH dropped by 77.70%, and Moxifloxacin of Nanjing Youke Pharmaceutical Co., Ltd. dropped by 53.07%. The CAGR of the sales value of Moxifloxacin in 2016-2020 is -3.76% in China.

The analyst predicts that with the effective relief of the COVID-19 epidemic, the sales of Moxifloxacin in the Chinese market will have a recovery growth in 2021-2025. In addition, there are 19 pharmaceutical companies that have entered the Chinese Moxifloxacin market by 2020. It is expected that the price of Moxifloxacin will decline with the addition of new manufacturers, and there is room for growth in sales volume and sales. At the same time, compared with similar drugs, Moxifloxacin has a broad antibacterial spectrum, strong curative effect and other advantages, so the sales volume of Moxifloxacin in China will maintain a growth trend.

Topics Covered:

  • The impact of COVID-19 on China's Moxifloxacin market
  • Sales value of China's Moxifloxacin 2016-2020
  • Competitive landscape of China's Moxifloxacin market
  • Prices of Moxifloxacin in China
  • Prices of Moxifloxacin in China by regions and manufacturers
  • Analysis of factors affecting the development of China's Moxifloxacin market
  • Prospect of China's Moxifloxacin market from 2021 to 2025
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bayer Vital GmbH
1 Relevant Concepts of Moxifloxacin
1.1 Indications for Moxifloxacin

1.2 Development of Moxifloxacin in China
1.3 Governmental Approval of Moxifloxacin in China
1.4 The Impact of COVID-19 on Moxifloxacin sales in China

2 Sales of Moxifloxacin in China, 2016-2020
2.1 Sales Value of Moxifloxacin
2.1.1 Overall Sales Value
2.1.2 Sales Value by Region
2.2 Sales Volume of Moxifloxacin
2.2.1 Overall Sales Volume
2.2.2 Sales Volume by Region
2.3 Sales of Moxifloxacin by Dosage Form in China, 2016-2020
2.3.1 Injection
2.3.3 Tablets
2.3.3 Eye Drop

3 Analysis of Major Moxifloxacin Manufacturers in China, 2016-2020
3.1 Analysis of Market Share of Major Moxifloxacin Manufacturers
3.1.1 Investigation on Market Share by Sales Value
3.1.2 Investigation on Market Share by Sales volume
3.2 Bayer Vital GmbH
3.2.1 Enterprise Profile
3.2.2 Sales of AVELOX (Bayer Vital GmbH’s Moxifloxacin) in China
3.3 Nanjing Yoko Pharmaceutical Group Co., Ltd.
3.3.1 Enterprise Profile
3.3.2 Sales of PRIMENOR (Nanjing Yoko Pharmaceutical Group Co., Ltd.’s Moxifloxacin) in China
3.4 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
3.4.1 Enterprise Profile
3.4.2 Sales of Chengdu Tiantaishan Pharmaceutical Co., Ltd.’s Moxifloxacin in China
3.5 Chengdu Zhengkang Pharmaceutical Co., LTD.
3.5.1 Enterprise Profile
3.5.2 Sales of Chengdu Zhengkang Pharmaceutical Co., LTD.’s Moxifloxacin in China
3.6 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.
3.6.1 Enterprise Profile
3.6.2 Sales of Fengreineng (Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd.’s Moxifloxacin) in China

4 Prices of Moxifloxacin for Different Manufacturers in China, 2020-2021
4.1 Bayer Vital GmbH (AVELOX)
4.2 Nanjing Yoko Pharmaceutical Group Co., Ltd. (PRIMENOR)
4.3 Chengdu Tiantaishan Pharmaceutical Co., Ltd.
4.4 Chengdu Zhengkang Pharmaceutical Co., LTD.
4.5 Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd. (Fengreineng)

5 Prospect of Chinese Moxifloxacin Market, 2021-2025
5.1 Influential Factors of Chinese Moxifloxacin Market Development
5.1.1 The Impact of COVID-19 on Chinese Moxifloxacin Market
5.1.2 Market Drivers and Opportunities
5.1.3 Market Threats and Challenges
5.2 Forecast on Market Size
5.3 Forecast on Market Trend

List of Charts
Chart Patent Information About Moxifloxacin Injection Registration in China
Chart Patent Information About Moxifloxacin Tablets Registration in China
Chart Patent Information About Moxifloxacin Eye Drop Registration in China
Chart Sales Value of Moxifloxacin Injection over the World
Chart Sales Value of Moxifloxacin Tablets over the World
Chart Sales Value of Moxifloxacin Eye Drop over the World
Chart Sales Value of Moxifloxacin Injection in China, 2016-2020
Chart Sales Value of Moxifloxacin Tablets in China, 2016-2020
Chart Sales Value of Moxifloxacin Eye Drop in China, 2016-2020
Chart Sales Value of Moxifloxacin Injection in China by Region, 2016-2020
Chart Sales Value of Moxifloxacin Tablets in China by Region, 2016-2020
Chart Sales Value of Moxifloxacin Eye Drop in China by Region, 2016-2020
Chart Sales Volume of Moxifloxacin Injection in China, 2016-2020
Chart Sales Volume of Moxifloxacin Tablets in China, 2016-2020
Chart Sales Volume of Moxifloxacin Eye Drop in China, 2016-2020
Chart Sales Volume of Moxifloxacin Injection in China by Region, 2016-2020
Chart Sales Volume of Moxifloxacin Tablets in China by Region, 2016-2020
Chart Sales Volume of Moxifloxacin Eye Drop in China by Region, 2016-2020
Chart Market Share by Sales Value of Top Moxifloxacin Injection Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Moxifloxacin Tablets Manufacturers in China, 2016-2020
Chart Market Share by Sales Value of Top Moxifloxacin Eye Drop Manufacturers in China, 2016-2020
Chart Sales Value and Volume of AVELOX in China, 2016-2020
Chart Sales Value and Volume of PRIMENOR in China, 2016-2020
Chart Sales Value and Volume of Chengdu Tiantaishan Pharmaceutical Co., Ltd.’s Moxifloxacin in China, 2016-2020
Chart Sales Value and Volume of Chengdu Zhengkang Pharmaceutical Co., LTD.’s Moxifloxacin in China, 2016-2020
Chart Sales Value and Volume of Fengreineng in China, 2016-2020
Chart Referential Prices of AVELOX in China by Region, 2020-2021
Chart Referential Prices of PRIMENOR in China by Region, 2020-2021
Chart Referential Prices of Chengdu Tiantaishan Pharmaceutical Co., Ltd.’s Moxifloxacin in China by Region, 2020-2021
Chart Referential Prices of Chengdu Zhengkang Pharmaceutical Co., LTD.’s Moxifloxacin in China by Region, 2020-2021
Chart Referential Prices of Fengreineng in China by Region, 2020-2021
Chart Forecast on Sales Value of Moxifloxacin Injection in China, 2021-2025
Chart Forecast on Sales Value of Moxifloxacin Tablets in China, 2021-2025
Chart Forecast on Sales Value of Moxifloxacin Eye Drop in China, 2021-2025
Chart Forecast on Sales Volume of Moxifloxacin Injection in China, 2021-2025
Chart Forecast on Sales Volume of Moxifloxacin Tablets in China, 2021-2025
Chart Forecast on Sales Volume of Moxifloxacin Eye Drop in China, 2021-2025
Note: Product cover images may vary from those shown

Loading
LOADING...

  • Bayer Vital GmbH
  • Nanjing Yoko Pharmaceutical Group Co., Ltd.
  • Chengdu Tiantaishan Pharmaceutical Co., Ltd.
  • Chengdu Zhengkang Pharmaceutical Co., LTD.
  • Jiangsu Zhengda Fenghai Pharmaceutical Co. Ltd
Note: Product cover images may vary from those shown

Background research defines the range of products and industries, which proposes the key points of the research. Proper classification will help clients understand the industry and products in the report.

Secondhand material research is a necessary way to push the project into fast progress. The analyst always chooses the data source carefully. Most secondhand data they quote is sourced from an authority in a specific industry or public data source from governments, industrial associations, etc. For some new or niche fields, they also "double-check" data sources and logics before they show them to clients.

Primary research is the key to solve questions, which largely influence the research outputs. The analyst may use methods like mathematics, logical reasoning, scenario thinking, to confirm key data and make the data credible.

The data model is an important analysis method. Calculating through data models with different factors weights can guarantee the outputs objective.

The analyst optimizes the following methods and steps in executing research projects and also forms many special information gathering and processing methods.

1. Analyze the life cycle of the industry to understand the development phase and space.
2. Grasp the key indexes evaluating the market to position clients in the market and formulate development plans
3. Economic, political, social and cultural factors
4. Competitors like a mirror that reflects the overall market and also market differences.
5. Inside and outside the industry, upstream and downstream of the industry chain, show inner competitions
6. Proper estimation of the future is good guidance for strategic planning.


 

Loading
LOADING...

Adroll
adroll